Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Biologicals
Femme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Safety, reactogenicity and immunogenicity study of different formulations of GlaxoSmithKline (GSK) Biologicals’ investigational RSV vaccine (GSK3003891A), in healthy women
To evaluate the reactogenicity and the safety of a single intramuscular dose of the investigational RSV vaccines, in healthy, non-pregnant women, during the first 30 days after vaccination. To evalua...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix™) co-administrated with GlaxoSmithKline Biologicals’ Hepatitis B vaccine (Engerix-B™) in healthy female subjects aged 9 - 15 years
•To demonstrate non-inferiority of the hepatitis B immune response at Month 7 when hepatitis B vaccine is co-administered with HPV-16/18 vaccine at Months 0, 1 and 6 (HPV+HepB group) as compared to wh...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Study to evaluate the efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated liquid human rotavirus (HRV) vaccine (444563), in healthy infants
To assess the efficacy of two doses of GSK Biologicals’ liquid HRV vaccine against severe RV GE caused by the circulating wild-type RV strains during the efficacy follow-up period. Criteria: The pri...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
A randomized, double-blind, placebo-controlled, multi-country and multi-center, phase IV study to demonstrate the efficacy of GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscularly in adults
To demonstrate the efficacy of Fluarix™ in the prevention of culture confirmed influenza A and/or B cases, for vaccine antigenically matched strains, when compared to the placebo group.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Safety and immunogenicity of a booster dose of new formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine
To demonstrate that the immunogenicity of at least one DTPa-HBV-IPV/Hib formulation is non-inferior to the licensed formulation in terms of seroprotection rates to diphtheria, tetanus, hepatitis B, po...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Study to assess reactogenicity and safety of co-administration of GlaxoSmithKline (GSK) Biologicals’ Poliorix and Infanrix when administered as a three-dose primary immunization course in healthy children of Russian Federation
Reactogenicity and safety assessment of co-administration of GlaxoSmithKline (GSK) Biologicals’ inactivated poliomyelitis vaccine PoliorixTM and GlaxoSmithKline (GSK) Biologicals’ DTPa-vaccine Infanri...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Immunogenicity and safety study of GSK Biologicals Kinrix when co-administered with GSK Biologicals Varivax
To demonstrate the non-inferiority of Kinrix co-administered with Varivax and M-M-RII compared to Kinrix co-administered with M-M-RII only in terms of diphtheria (D), tetanus (T), pertussis (PT), fil...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
A phase II/III, observer-blind, multicountry, multicentre, randomized study to demonstrate the superiority in terms of immunogenicity of AS25 adjuvanted influenza vaccine administered in adults aged 50 years and older compared to Fluarix™
•To demonstrate that the immune response induced by FluAS25 in elderly adults is superior to that induced by Fluarix, 21 days following vaccination for each vaccine strain. •To demonstrate that the ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
A phase II, open, randomized study in adults aged between 18 and 60 years designed to evaluate the reactogenicity and immunogenicity of a 1- and 2-dose prime-boost concept of pandemic monovalent (H5N1) influenza vaccine (split virus formulation) adjuvanted with AS03, administered according to different vaccination schedules
•To assess if the humoral immune response induced by a booster dose of the candidate vaccine given 6 months after a priming vaccination with a single dose of the candidate vaccine formulated from an h...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Observer-blinded, randomised, controlled, phase I/II study, to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ candidate tuberculosis vaccines M72/AS01B and M72/AS02A when administered intramuscularly according to a vaccination schedule of 0, 1 month, to healthy PPD-negative adults aged 18 to 50 years
To evaluate the safety and reactogenicity of GSK Biologicals’ candidate M72/AS02A and M72/AS01B tuberculosis vaccines and the comparator vaccines (Mtb72F/AS02A, M72/Saline and AS01B) when given accord...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
19
20
21
22
23
24
25
26
27
28
Suivant